Figure 2.
Renal survival in patients with and without pathogenic mutations in podocyte genes. Development of ESRD was 29% in patients without pathogenic mutation compared with 71% in patients with proven mutation (P = 0.0001; Fisher's exact test). Sixty-three percent (nongenetic) compared with 22% (genetic) of the patients preserved a normal renal function over the mean follow-up time of the study (8.6 years).